Drug resistance continues to be a major challenge in the treatment of HIV-1 infection. Virtually all currently available antiretroviral medications inhibit the viral reverse transcriptase or protease. Enfuvirtide is the first fusion inhibitor approved by the US Food and Drug Administration (USFDA) for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced patients. Fusion inhibitor A class of antiretroviral drugs that work on the outside of the host CD4 cell to prevent HIV from fusing with and infecting it.
Fusion inhibitors act by binding to an envelope protein and blocking the structural changes necessary for the virus to fuse with the host CD4 cell. If HIV cannot penetrate the host cell membrane and infect the cell, It can't replicate within the host cell. Enfuvirtide The introduction of this drug molecule represents an…
